Skip to main content

Table 3 Results

From: Sparing the contralateral submandibular gland without compromising PTV coverage by using volumetric modulated arc therapy

Site   SM CL SM CL (non-sparing) PG IL PG IL (non-sparing) PG CL PG CL (non-sparing) Sp C Sp C (non-sparing) V B ≥95% V E ≥95%
A mean 33.7 51.5 34.2 33.3 21.8 21.4 42.1 41.9 99.3 98.9
  range (46.5-57.3) (24.7-41.6) (16.6-54.3) (16.3-53.2) (12.2-31.8) 14.2-32.1) (37-50) (35.8-49) (98.9-99.9) (98.2-99.5)
B mean 32.4 49 27.9 27.8 22 21.9 36.4 36.3 99.7 98.5
  range (44.3-52.8) (29.7-39.5) (16.4-55.5) (16-55.7) (16.7-30.6) (16.7-30.3) (23-49.8) (23-49.8) (99-99.9) (97.9-98.9)
C mean 35.1 47.1 28.7 29.1 21.9 22 40 39.8 98.5* 98.9
  range (43.7-52.4) (26.6-40.6) (16.5-48.2) (17-46.3) (13.6-30.9) (14.5-30.7) (30-44.9) (29.7-45.3) (96.2-99.6) (97.9-98.9)
D mean 33.4 46.4 21.2 21 16.2 16 36.4 36 99.6 98.3
  range (42.2-51.8) (30-36.8) (12.7-35.7) (12.4-35.6) (10.7-26.1) (10.3-26.3) (24.7-41) (24.4-41.2) (99.1-99.9) (97.6-98.9)
  1. A: oropharynx, elective dose 57.75 Gy (14 patients) Doses in Gy
  2. B: larynx/hypopharynx, elective dose 57.75 Gy (7 patients) Sp C: spinal cord
  3. C: oropharynx, elective dose 54.25 Gy (6 patients)
  4. D: larynx/hypopharynx, elective dose 54.25 Gy (4 patients)
  5. V B ≥95%:% of PTV boost receiving ≥95% of the prescribed dose
  6. V E ≥95%:% of PTV elective receiving ≥95% of the prescribed dose
  7. *: in 1 patient with T1 carcinoma of the soft palate, 96.2% of PTVboost received 95% of prescribed dose, this was accepted because of the fact that a large part of the PTVboost consisted of air.